EP4455155A1 — Targeting ligand and use thereof
Assigned to Chengdu Xinzhenghe Pharmaceutical Technology Co Ltd · Expires 2024-10-30 · 2y expired
What this patent protects
The present invention is suitable for the technical field of nucleic acid drug delivery; specifically provided are a nucleic acid delivery compound, a liver-targeting nucleic acid ligand and the use thereof. Provided in the present invention are a compound as represented by formu…
USPTO Abstract
The present invention is suitable for the technical field of nucleic acid drug delivery; specifically provided are a nucleic acid delivery compound, a liver-targeting nucleic acid ligand and the use thereof. Provided in the present invention are a compound as represented by formula (Z-1), and compounds as represented by formula (I) and (II). An oligonucleotide conjugate provided in the embodiments of the present invention can improve the binding efficiency of a targeting moiety to a cell or a cell receptor, and increase the effect of RNA interference.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.